1. Sweden Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Midsona AB Class A

Midsona AB Class A

14.70
SEK
0.00
(0.00%)
0.77EPS
19.74P/E
2.21BMarket Cap
Oct 22Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
23.74
23.84
30.75
42.65
37.5
55.12
56.86
50.73
55.66
52.37
26.08
25.63
24.96
24.49
Basic EPS, GAAP
1.32
1.63
1.73
1.1
1.47
2.49
1.79
2.41
1.31
-6.73
-0.36
0.32
0.07
0.77
Free Cash Flow per Basic Share
2.1
1.37
2.2
0.51
2.18
2.88
2.9
2.67
-1.81
2.26
2.15
0.81
1.34
1.04
Dividend per Share
0.29
0.6
0.65
0.76
0.82
1.12
1.07
1.11
1.27
- -
- -
- -
0.2
0.42
Book Value per Share
22.72
24.04
23.73
28.06
29.89
31.44
35.67
35.53
39.52
21.19
20.54
21.1
20.17
21.11
Tangible Book Value per Share
-4.35
-3.97
-5.14
-12.29
-11.17
-16.12
-11.31
-14.99
-6.72
0.43
0.42
1.11
1.11
1.6
Basic Weighted Avg Shares
39
39
38
41
57
52
54
73
68
74
145
145
145
145
Sales/Revenue/Turnover
916
920
1,174
1,744
2,146
2,852
3,081
3,709
3,773
3,899
3,793
3,727
3,630
3,561
Operating Margin (%)
6.99
6.63
4.17
5.22
6.52
6.8
6.17
6.79
4.37
-11.8
0.55
3.49
1.46
4.24
Depreciation Expense
14
14
19
25
35
52
114
147
156
161
157
152
142
- -
Net Income, GAAP
51
63
66
45
84
129
97
176
89
-501
-53
47
10
112
Effective Tax Rate (%)
3.77
- -
- -
22.41
25
20.86
16.38
13.73
22.61
- -
- -
37.33
58.33
8.94
Profit Margin (%)
5.57
6.85
5.62
2.58
3.91
4.52
3.15
4.75
2.36
-12.85
-1.4
1.26
0.28
3.15
Working Capital
55
51
67
177
152
310
399
293
566
621
500
483
656
742
LT Debt
149
148
250
696
665
1,124
1,408
1,526
1,314
776
608
465
550
541
Total Equity
710
751
877
1,349
1,550
1,630
2,322
2,313
2,875
3,082
2,987
3,068
2,933
3,070
Return on Invested Capital (%)
6.7
- -
- -
3.83
4.58
5.47
4.22
5.54
2.92
- -
- -
2.16
0.67
3.81
Return on Capital (%)
6.6
- -
- -
3.56
4.5
5.86
3.8
5.17
2.8
- -
- -
2.06
0.64
3.97
Return on Common Equity (%)
7.31
8.62
8.11
4.04
5.8
8.11
4.91
7.59
3.43
-16.82
-1.75
1.55
0.33
3.7

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
65
61
58
LT Borrowings
491
- -
- -
LT Finance Leases
59
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
145
145
145
Market Capitalization
1,556
1,760
2,211

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,251
1,376
1,313
Cash, Cash Equivalents & STI
316
340
282
Accounts Receivable, Net
327
393
325
Inventories
552
592
641
Total Current Liabilities
595
603
571
Payables & Accruals
- -
- -
- -
ST Debt
65
61
58
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.27%
5.35%
-4.4%
Free Cash Flow
15.81%
-62.18%
65.25%
Net Income, GAAP
-90.41%
-213.83%
-78.72%
Sales/Revenue/Turnover
13.09%
-0.4%
-2.6%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
929
918
919
961
3,727
2025
937
865
- -
933
3,630
2026
893
870
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.11
0.02
0.06
0.13
0.32
2025
0.05
-0.1
- -
0.23
0.07
2026
0.56
0.08
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
0.2
- -
- -
0.2
2026
- -
0.22
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Nils Johan Henrik Hjalmarsson
Full Time Employees
697
Sector
Health technology
Industry
Pharmaceuticals: other
Address
Dockplatsen 16 Malmö SN Sweden 211 19
IPO Date
Jan 1, 1966
Website
midsona.com
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Midsona AB (publ) develops, manufactures and markets health and well-being products, with a focus on organic, plant-based and natural foods; it operates primarily in the consumer health and wellness industry through three divisions covering Nordics, North Europe and South Europe. The company offers a broad portfolio of products including plant-based foods such as grains, flakes, seeds, vegetables, pasta, rice, nuts, dried fruits, berries, oils, spices, muesli and fruit purees under brands like Earth Control and Kung Markatta; organic and vegan beauty products encompassing hair, body and face care under Urtekram and Urtekram Beauty; roasted grains, cereals, corn and rice cakes, teas and dietary supplements under Friggs and Davert; vegetable proteins and fresh plant-based items under Vegetalia; cooking and baking essentials like oils, grains, pasta, bouillon and flours under Celnat; as well as organic and biodynamic goods including breads, beverages, cold cuts, pasta sauces, pesto, sugar, syrups, nuts, seeds and tea under Helios and Happy Bio. Midsona sells these products through pharmacies, grocery chains, health food stores, food service operators and online channels to consumers seeking healthy, sustainable alternatives. Founded in 1892 and headquartered in Malmö, Sweden, the company maintains a strong presence in the Nordic countries (Sweden, Denmark, Finland, Norway), with expanding operations in Germany, France and Spain. In recent developments, Midsona announces a restructuring program in October 2025 to streamline operations, reduce overhead costs and accelerate margin improvements, targeting annual savings of SEK 20 million by Q1 2026 with related costs of SEK 15 million; this follows improved Q3 2025 profitability, with EBIT up 40% year-over-year to SEK 45 million and own-brand organic sales growth of 8.2%, despite a 2.6% overall net sales decline due to currency effects and Spanish capacity issues.